Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-γ and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2

Journal of Immunology

Volumn 169, Issue 8, 2002, Pages 4467-4474

  Wigginton, Jon M ^a   Lee, Jong Keuk ^a   Wiltrout, Theresa A ^a   Alvord, W Gregory ^a   Hixon, Julie A ^a   Subleski, Jeffrey ^a   Back, Timothy C ^a   Wiltrout, Robert H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; KNOCKOUT MOUSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 0037108519     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.8.4467     Document Type: Article

References (28)

1. Nakamura, K., H. Okamura, M. Wada, K. Nagata, and T. Tamura. 1989. Endotoxin-induced serum factor that stimulates γ interferon production. Infect. Immun. 57:590.
2. Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, and K. Hattori. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88.
3. Dinarello. C. A. 1999. Interleukin-18. Methods 19:121.
4. Okamura, H., H. Tsutsui, S. Kashiwamura, T. Yoshimoto, and K. Nakanishi. 1998. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv. Immunol. 70:281.
5. Tsutsui, H., K. Nakanishi, K. Matsui, K. Higashino, H. Okamura, Y. Miyazawa, and K. Kaneda. 1996. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. 157:3967.
6. Dao, T., K. Ohashi, T. Kayano, M. Kurimoto, and H. Okamura. 1996. Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell. Immunol. 173:230.
7. Dao, T., W. Z. Mehal, and I. N. Crispe. 1998. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J. Immunol. 161:2217.
8. Osaki, T., W. Hashimoto, A. Gambotto, H. Okamura, P. D. Robbins, M. Kurimoto, M. T. Lotze, and H. Tahara. 1999. Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18). Gene Ther. 6:808.
9. Tan, J., B. E. Crucian, A. E. Chang, E. Aruga, A. Aruga, S. E. Dovhey, K. Tanigawa, and H. Yu. 1998. Interferon-γ-inducing factor elicits antitumor immunity in association with interferon-γ production. J. Immunol. 21:48.
10. Fukumoto, H., M. Nishio, K. Nishio, Y. Heike, H. Arioka, H. Kurokawa, T. Ishida, K. Fukuoka, T. Nomoto, Y. Ohe, et al. 1997. Interferon-γ-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jpn. J. Cancer Res. 88:501.
11. Hashimoto, W., T. Osaki, H. Okamura, P. D. Robbins, M. Kurimoto, S. Nagata, M. T. Lotze, and H. Tahara. 1999. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand. J. Immunol. 163:583.
12. Osaki, T., J. M. Peron, Q. Cai, H. Okamura, P. D. Robbins, M. Kurimoto, M. T. Lotze, and H. Tahara. 1998. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ and IL-12-independent antitumor effects. J. Immunol. 160:1742.
13. Micallef, M. J., K. Yoshida, S. Kawai, T. Hanaya, K. Kohno, S. Arai, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, et al. 1997. In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 43:361.
14. Wigginton, J. M., K. L. Komschlies, T. C. Back, J. L. Franco, M. J. Brunda, and R. H. Wiltrout. 1996. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 88:38.
15. Hoshino, T., R. H. Wiltrout, and H. A. Young. 1999. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. 162:5070.
16. + cytotoxic T lymphocytes by interleukin-18. Jpn. J. Cancer Res. 89:1041.
17. Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, and M. Kurimoto. 1997. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. 158:1541.
18. Ushio, S., M. Namba, T. Okura, K. Hattori, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii, et al. 1996. Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J. Immunol. 156:4274.
19. Son, Y. I., R. M. Dallal, R. B. Mailliard, S. Egawa, Z. L. Jonak, and M. T. Lotze. 2001. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells. Cancer Res. 61:884.
20. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95:7556.
21. IIIindium-oxine. J. Immunol. Methods 43:319.
22. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83.
23. Wigginton, J. M., E. Gruys, L. Geiselhart, J. Subleski, K. L. Komschlies, J. W. Park, T. A. Wiltrout, K. Nagashima, T. C. Back, and R. H. Wiltrout. 2001. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse 1L-2 therapy. J. Clin. Invest. 108:51.
24. Yamanaka, K., I. Hara, H. Nagai, H. Miyake, K. Gohji, M. J. Micallef, M. Kurimoto, S. Arakawa, and S. Kamidono. 1999. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol. Immunother. 48:297.
25. Coughlin, C. M., K. E. Salhany, M. Wysocka, E. Aruga, H. Kurzawa, A. E. Chang, C. A. Hunter, J. C. Fox, G. Trinchieri, and W. M. F. Lee. 1998. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Immunol. 101:1441.
26. Oshikawa, K., F. Shi, A. L. Rakhmilevich, P. M. Sondel, D. M. Mahvi, and N. S. Yang. 1999. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA. Proc. Natl. Acad. Sci. USA 96:13351.
27. Okamoto. M., S. Kato, K. Oizumi, M. Kinoshita, Y. Inoue, K. Hoshino, S. Akira, A. N. J. McKenzie, H. A. Young, and T. Hoshino. 2002. Interleukin-18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 99:1289.
28. Volpert, O. V., T. Zaichuk, W. Zhou, F. Reiher, T. A. Ferguson, P. M. Stuart, M. Amin, and N. P. Bouck. 2002. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 8:349.